FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a positive end induction PET (e-PET). The aim of this study was to evaluate the clinical characteristics of patients with a positive e-PET as a secondary end point of the HD0801 study. A total of 519 patients with advanced-stage de novo Hodgkin lymphoma received initial treatment and underwent an i-PET. Patients with negative results continued the standard treatment. i-PET negative patients were then evaluated for response with an e-PET and those patients found to have a positive one were also then given a salvage therapy. Among 409 i-PET negative, 16 interrupted the therapy, 393 patients were evaluated with an e-PET, and 39 were positive. Sixteen out of 39 underwent a diagnostic biopsy and 15 were confirmed as HD. Seventeen out of 39 e-PET were reviewed according to the Deauville Score and, in sixteen, it was confirmed positive (10 DS 5, 6 DS 4). With the exception of high LDH value at diagnosis (p = 0.01; HR 95% CI 1.18-4.89), no clinical characteristics were significantly different in comparison with e-PET negative patients. Positive e-PET after a negative i-PET has a worse outcome when compared with i-PET positive patients salvaged with therapy intensification. It was not possible to identify clinical characteristics associated with a positive e-PET.

中文翻译：

---

来自前瞻性HD08-01 FIL研究的中期PET阴性，中期PET阳性的患者的临床特征。

已证实在晚期霍奇金淋巴瘤患者的治疗过程中早期进行的FDG正电子发射断层扫描（PET）对于无进展生存至关重要。一组中期PET阴性的患者显示出末端诱导PET阳性。这项研究的目的是评估e-PET阳性作为HD0801研究的次要终点的患者的临床特征。共有519名晚期新发霍奇金淋巴瘤患者接受了初始治疗并接受了i-PET。结果阴性的患者继续接受标准治疗。然后评估i-PET阴性患者使用e-PET的反应，然后对发现阳性的患者进行挽救治疗。在409例i-PET阴性中，有16例中断了治疗，393例患者接受了e-PET评估，其中39例阳性。39例中有16例进行了活检，15例被确认为HD。根据Deauville评分对39份e-PET中的17份进行了审查，在16份中，证实为阳性（10 DS 5、6 DS 4）。除诊断时LDH值高（p = 0.01； HR 95％CI 1.18-4.89）外，与e-PET阴性患者相比，临床特征无显着差异。与通过治疗强化抢救的i-PET阳性患者相比，在i-PET阴性后，阳性e-PET的预后较差。无法确定与阳性e-PET相关的临床特征。根据Deauville评分对39份e-PET中的17份进行了审查，在16份中，证实为阳性（10 DS 5、6 DS 4）。除诊断时LDH值高（p = 0.01； HR 95％CI 1.18-4.89）外，与e-PET阴性患者相比，临床特征无显着差异。与通过治疗强化抢救的i-PET阳性患者相比，在i-PET阴性后，阳性e-PET的预后较差。无法确定与阳性e-PET相关的临床特征。根据Deauville评分对39份e-PET中的17份进行了审查，在16份中，证实为阳性（10 DS 5、6 DS 4）。除诊断时LDH值高（p = 0.01； HR 95％CI 1.18-4.89）外，与e-PET阴性患者相比，临床特征无显着差异。与通过治疗强化抢救的i-PET阳性患者相比，在i-PET阴性后，阳性e-PET的预后较差。无法确定与阳性e-PET相关的临床特征。与通过治疗强化抢救的i-PET阳性患者相比，在i-PET阴性后，阳性e-PET的预后较差。无法确定与阳性e-PET相关的临床特征。与通过治疗强化抢救的i-PET阳性患者相比，在i-PET阴性后，阳性e-PET的预后较差。无法确定与阳性e-PET相关的临床特征。